<DOC>
	<DOC>NCT02093260</DOC>
	<brief_summary>To Asses the Immunogenicity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)</brief_summary>
	<brief_title>Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)</brief_title>
	<detailed_description>Too see percentage of subjects with HI titer &gt;= 1:40, 28 days after two doses in infants and children (6 months-8 years old) and one dose in children 9-11 years old for each strain.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Parents have been informed properly regarding the study and signed the informed consent form Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial Subjects concomitantly enrolled or scheduled to be enrolled in another trial Evolving mild, moderate, or severe illness, especially infectious diseases or fever (axillary temperature &gt;=37oC) Known history of allergy to egg and/or chicken protein or any other component of the vaccines Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection Subject who has received a treatment likely to alter the immune response in the previous 4 weeks (intravenous immunoglobulins, bloodderived products or long term corticotherapy (&gt;2 weeks)). Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives. Subjects has been immunized with influenza vaccine within 1 year Subjects receives any vaccination within 1 months before and after immunization of Flubio.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Flubio Vaccine (Influenza HA)</keyword>
	<keyword>Infants</keyword>
	<keyword>Children</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>